Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: Insight from the national health and nutrition examination survey III (NHANES-III)

Circulation

Volumn 130, Issue 7, 2014, Pages 546-553

  Doran, Bethany ^a   Guo, Yu ^a   Xu, Jinfeng ^a   Weintraub, Howard ^a   Mora, Samia ^b   Maron, David J ^c   Bangalore, Sripal ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cholesterol; mortality

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ADULT; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPARATIVE STUDY; DIET RESTRICTION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; NUTRITION; PROGNOSIS; TIME; TRENDS;

ADULT; CARDIOVASCULAR DISEASES; COHORT STUDIES; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MORTALITY; NUTRITION SURVEYS; PROGNOSIS; TIME FACTORS;

EID: 84906089217     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.010001     Document Type: Article

References (46)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) fnal report. Circulation. 2002;106:3143-3421.
2. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsene T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Arch Mal Coeur Vaiss. 2004;97:1019-1030.
3. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipid-emia and prevention of cardiovascular disease in the adult: 2009 recommendations. Can J Cardiol. 2009;25:567-579.
4. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med. 2012;172:1707-1710.
5. Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipo-proteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem. 2011;57:482-489.
6. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med. 1999;246:341-355.
7. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-485.
8. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem. 2005;12:1931-1945.
9. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
10. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309-316.
11. Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem. 2008;54:11-13.
12. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med. 2011;270:65-75.
13. Third National Health and Nutrition Examination Survey (NHANES III). NHANES III household adult data fle documentation: ages 17+. 1996. http://archive.nlm.nih.gov/proj/dxpnet/nhanes/docs/doc/nhanes3/adult/adult.html. Accessed December 1, 2013.
14. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
16. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentri-fugation reference measurement procedures. Clin Chem. 2010;56:977-986.
17. Schectman G, Patsches M, Sasse EA. Variability in cholesterol measurements: comparison of calculated and direct LDL cholesterol determinations. Clin Chem. 1996;42:732-737.
18. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem. 2002;48:236-254.
19. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27, 331 women. Clin Chem. 2009;55:888-894.
20. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-S45.
21. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118:993-1001.
22. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
23. World Health Organization. Use of glycated haemoglobin (Hba1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. 2011. http://www.who.int/diabetes/publications/report-hba1c-2011.pdf. Accessed December 1, 2013.
24. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158-161.
25. Klein S, Allison DB, Heymsfeld SB, Kelley DE, Leibel RL, Nonas C, Kahn R. Waist circumference and cardiometabolic risk. Diabetes Care. 2007;30:1647-1652.
26. Centers for Disease Control and Prevention. NHANES tutorial website. http://www.cdc.gov/NCHS/Tutorials/Nhanes/index.htm. Accessed December 10, 2013.
27. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Toronto, Canada: Academic Press Inc; 1977.
28. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44:2107-2114.
29. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mel-litus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813-819.
30. Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou K, Panotopoulos G. Assessment and clinical relevance of non-fasting and postprandial triglyc-erides: an expert panel statement. Curr Vasc Pharmacol. 2011;9:258-270.
31. McBride PE. Triglycerides and risk for coronary heart disease. JAMA. 2007;298:336-338.
32. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol. 1997;17:239-245.
33. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM. Triglycerides and cardiovascular disease a scientifc statement from the American Heart Association. Circulation. 2011;123:2292-2333.
34. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epide-miologic insights for current opinion in cardiology. Curr Opin Cardiol. 2009;24:345.
35. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death: the Framingham study. Arch Intern Med. 1981;141:1128-1131.
36. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-1109.
37. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO. Overall and coronary heart disease mortality rates in relation to major risk factors in 325, 348 men screened for the MRFIT: Multiple Risk Factor Intervention Trial. Am Heart J. 1986;112:825-836.
38. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155:487-495.
39. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041-1046.
40. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation. 2002;106:3031-3036.
41. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfeld M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicen-tre randomised controlled trial. Lancet. 2003;361:1149-1158.
42. MRC/BHF Heart Protection Study of cholesterol lowering with simv-astatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
43. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
44. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfast-ing lipid levels: infuence of normal food intake on lipids, lipopro-teins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008;118:2047-2056.
45. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipo-protein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol. 2002;22:1918-1923.
46. Van Dieren S, Nöthlings U, Van Der Schouw Y, Spijkerman A, Rutten G, Sluik D, Weikert C, Joost H, Boeing H, Beulens J. Non-fasting lip-ids and risk of cardiovascular disease in patients with diabetes mellitus. Diabetologia. 2011;54:73-77.